The effect of lipegfilgrastim on hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies
Journal Title: OncoReview - Year 2016, Vol 6, Issue 2
Abstract
Megachemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) is a standard treatment option in patients below 70 years of age with multiple myeloma (MM) as well as with relapsed and refractory lymphomas. Recombinant granulocyte colony-stimulating factors (G-CSF) are commonly used to accelerate bone marrow recovery after chemotherapy and reduce the duration of severe neutropenia. Lipegfilgrastim is a glicopegylated G-CSF with prolonged action registered for adult patients with malignant neoplasms in order to reduce the duration of neutropenia and the incidence of febrile neutropenia (FN). So far, there is not enough data to confirm the effectiveness and safety of this drug in patients with hematological malignancies including those undergoing auto-PBSCT. The aim of this study was to determine the effect of lipegfilgrastim on hematopoietic regeneration and supportive care after auto-PBSCT in patients with lymphoproliferative malignancies. The study population consisted of 30 patients (12 female and 18 male; median age: 50 years ± 13), including 13 patients with MM, 5 with Hodgkin’s lymphoma (HL) and 12 with non-Hodgkin’s lymphoma (nHL). The median number of transplanted CD34+ cells was 3.96 ± 1.56 × 10^6/kg of body mass. On day +1 after auto-PBSCT, the patients received lipegfilgrastim in a single 6 mg subcutaneous injection. The control group consisted of 32 patients (13 female and 19 male; median age: 50 years ± 6.4), including 13 with MM, 8 with HL and 11 with nHL, who received subcutaneous filgrastim in a dose of 5 μg/kg/day from day +1 after transplantation and continued to an absolute neutrophil count (ANC) > 1.5 × 10^9/L. There was no significant difference in the time of regeneration ANC > 0.5 × 10^9/L which was 10.65 ± 1.00 vs. 11.51 ± 2.29 days respectively in the study and control group. Similar observations were noted regarding the duration of febrile neutropenia (2.16 ± 2.22 vs. 1.70 ± 4.17 days; p = 0.998), regeneration of platelets (PLT) > 20 × 10^9/L (12.41 ± 2.41 vs. 13.82 ± 4.48 days; p = 0.233) and demand for transfusion of red blood cells (0.76 ± 1.07 vs. 1.33 ± 2.33 units; p = 0.414) and platelets (11.5 ± 6.9 vs. 19.2 ± 17.7 units; p = 0.08). Different results were observed for the length of hospitalization, which was significantly shorter in the lipegfilgrastim group (16.14 ± 14 vs. 24.46 ± 6.79 days; p = 0.000). Lipegfilgrastim is as effective as filgrastim with regards to the regeneration of the hematopoietic system, duration of febrile neutropenia, demand for transfusion of blood products and significantly reduces hospitalization in patients with lymphoproliferative malignancies after auto-PBSCT.
Authors and Affiliations
Ewa Frączak, Jarosław Dybko, Justyna Rybka, Monika Biedroń, Izabela Dereń-Wagemann, Donata Urbaniak-Kujda, Kazimierz Kuliczkowski, Tomasz Wróbel
Keywords
Related Articles
- EP ID EP78743
- DOI 10.5604/20828691.1207984
- Views 166
- Downloads 0
Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2010
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of gastrointestinal tract. Advances in the understanding of the molecular mechanisms of GIST pathogenesis have resulted for last years in the...
The influence of socio-demographic factors on making a decision related to the disease and treatment in women with breast cancer
Introduction. Socio-demographic factors may affect the decision making associated with the disease and the long-term results of treatment.Objective. Exploring the relationship between socio-demographic factors of women t...
Zastosowanie filtrów żylnych w profilaktyce przeciwzakrzepowej przed zabiegami onkologicznymi
Jedną z najczęstszych przyczyn powikłań i zgonów pacjentów onkologicznych jest żylna choroba zakrzepowo-zatorowa. Postępowanie lecznicze w tej grupie chorych sprowadza się przede wszystkim do odpowiedniej farmakoterapii....
Targeted therapies for chronic myeloid leukemia and cardiovascular system
Morbidity of chronic myeloid leukemia is recorded in elderly population, in patients with coexisting significant risk factors for atherosclerosis and heart diseases. Molecularly targeted therapy, imatinib, dasatinib and...
Chemotherapy-related nephrotoxicity
The development of oncology and increasing prevalence of cancer is associated with rapidly growing group of patients treated with chemotherapeutic agents, which, with the benefits of their use, poses a risk of side effec...